Upbeat On Injectables, Aurobindo Hiking Capacities
Acquisition In Emerging Markets Possible
Executive Summary
Aurobindo expects revenues from injectables to increase to $650-700m over the next three years as its Vizag plant gets commissioned in a year’s time. Apart from seeking organic growth, the company is keeping an eye out for acquisitions in emerging markets though big-ticket ones are ruled out.
You may also be interested in...
It’s Deal Time: Aurobindo on M&A, Divestment Path
What value do PE funds see in Aurobindo Pharma’s injectables business as the company looks for a partner? Why is Aurobindo looking for acquisitions in India as it sets a domestic revenue target of $133m in three years from the formulations business? Scrip takes a look.
Aurobindo Expects Interim Phase II/III COVID-19 Vaccine Data By July
Aurobindo expects the first data readouts from the Phase II/III clinical trials of its partnered COVID-19 vaccine by July. While making progress in biosimilars development, the Indian company also plans to invest substantially in new API capacity.
Indian Alliance For Pfizer/BioNTech’s COVID-19 Vaccine?
Pfizer is unlikely to tie up with Indian companies soon for manufacture of its COVID-19 vaccine as it has built capacity for the first phase. However, as discussions to supply to the COVAX facility and developing countries progress, it could evaluate such opportunities later.